In February, India’s pharmaceutical market experienced significant month-on-month growth of nearly 9%, according to data from the market research firm Pharmatrac. The performance across therapy areas was generally positive, except for the respiratory segment, which saw a decline in both value and units.
Cardiology and anti-infective treatments emerged as the top two therapy areas based on Pharmatrac’s findings. Sheetal Sapale, VP Commercial at Pharmatrac, expressed satisfaction with the industry’s performance, noting a close to 9% overall growth. With the exception of the respiratory segment, all therapy areas demonstrated robust growth.
While unit growth remained challenging across most therapy areas, there was a positive trend in terms of value growth. The growth observed in February was primarily attributed to price increases and the introduction of new products, a trend consistent with the previous year.
The growth drivers for the month included the cardiac, anti-infective, and anti-neoplastic segments, which exhibited relatively strong volume-driven growth compared to other therapy areas where growth was primarily attributed to price increases or new product introductions.
Augmentin, an antibiotic drug, retained its position as the top-selling product with a 22% growth rate in February. Other leading products included the cholesterol drug Rosuvas, thyroid drug Thyronorm, Liv 52, and antacid Pan, all of which demonstrated double-digit growth in both value and units. As reported by Business Journal, Rybelsus, an anti-diabetic medication, maintained triple-digit growth observed over several months, while Ecosprin AV and Electral also showed significant double-digit growth rates.
